US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Observe Medical - Company presentation with trading update

Oslo, 26 June 2026.  With reference to today's webcast, please find enclosed the presentation. Key topics: · Market penetration and expanding portfolio is driving strong growth in order intake and sales · Continued progress in India · UnoMeter Safeti Max - foundation for clinical leadership and performance - delivering on key challenges · Distributors covering 28 countries has placed orders of UnoMeter™ Safeti Max  · Paving the way for a launch of Sippi A recording of the presentation is also available at:https://qcnl.tv/p/eTRN97XxaZRzl4F69giI4Q 

Observe Medical ASA: Invitation to presentation with trading update 26 June, 2026

Oslo, 10 June 2026 – Observe Medical ASA (OSE: OBSRV) (“the Company” or “Observe Medical”) is pleased to host a presentation with trading update Friday, 26 June 2026. Observe Medical invites investors, analysts, and other stakeholders to the presentation which will take place virtually Friday 26 June 2026, at 10:00 CEST, and streamed via webcast at the following link: https://qcnl.tv/p/eTRN97XxaZRzl4F69giI4Q   The main focus will be an update on our inbound order trajectory and the first impressions from the commercial launch of UnoMeter

Observe Medical ASA - Annual General Meeting held

Oslo, 29 May 2026 The annual general meeting of Observe Medical ASA (the "Company" or "Observe Medical", Euronext Expand ticker "OBSRV") was held today, on 29 May 2026 at 10:00 hours (CEST), at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway. All resolutions were made in accordance with the proposals from the board of directors and the nomination committee. A copy of the signed minutes from the Annual General Meeting of Observe Medical ASA is attached. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading

Acceptance of Clinical Data for Scientific Publication - UnoMeter[TM] Safeti[TM] Max

Oslo, 26 May 2026 – Observe Medical ASA (the "Company" or "Observe Medical") is pleased to announce that an Abstract with in vitro clinical data related to the Company’s UnoMeter[TM] Safeti[TM] Max has been accepted for presentation and publication by the International Continence Society. The accepted Abstract presents findings from in vitro studies evaluating the product’s ability to protect patients from Catheter Associated Urinary Tract infection (CAUTI), the most common hospital-acquired infection and a major global healthcare burden, representing a multi-billion-dollar annual cost

Observe Medical ASA - Notice of Annual General Meeting

Oslo, 8 May 2026 - Observe Medical ASA (OBSRV): The annual general meeting of Observe Medical ASA will be held on Friday, 29 May 2026, at 10:00 (CEST). The annual general meeting will be held at Dronning Eufemias gate 16, 2nd floor, 0191 Oslo, Norway. The notice of the annual general meeting is attached, together with the attendance and proxy forms. The notice has been sent to shareholders with known addresses, and is also available on the Company's website www.observemedical.com  For further information, please contact: Jørgen

Observe Medical Annual Report for 2025

Oslo, April 30, 2026 – Observe Medical ("the Company" or "Observe Medical") has today published its Annual Report for 2025. The report is attached to this notice in ESEF and PDF format and is also available on the company's website under the Investor Relations section.  This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. For further information, please contact: Jørgen Mann, CEO Observe MedicalMobile: +45 408 67 558E-mail: jorgen.mann@observemedical.com Johan Fagerli, CFO Observe MedicalMobile: +47 958

OBSERVE MEDICAL ASA: Mandatory notification of trades by primary insiders and close associate

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has been informed that Glimt Invest AS, a close associate of Terje Bakken, Chairman of the Board and primary insider of the Company, has purchased 182,000 shares in the Company. Jørgen Mann, Chief Executive Officer of the Company, has purchased 50,000 shares in the Company. Johan Fagerli, Chief Financial Officer of the Company, has purchased 30,000 shares in the Company. For further details, please refer to the attached notification forms. This information is subject to the

OBSERVE MEDICAL ASA: Mandatory notification of trade – grant of share options to primary insider

Oslo, 9 April 2026 Observe Medical ASA ("Observe Medical" or the "Company", OSE ticker: OBSVR) has today granted 250,000 share options to primary insider and CEO of the Company, Jørgen Mann. Each share option gives the right to subscribe for or purchase one share in the Company or to receive a cash payment of a NOK amount for each exercised option equal to the market price of the Company's shares less the exercise price. The Company's board of directors shall, at its sole discretion, decide whether options that have been duly exercised shall be settled by either new shares, treasury

Observe Medical - Strengthens strategic position in India through an exclusive distribution agreement

Oslo, 25 March 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces that its journey into the strategically important Indian market has reached a new level through the signing of an exclusive distribution agreement with a leading local partner. This replaces the previously announced LOI. The partner is a historical distributor of UnoMeter™ and brings deep market knowledge, an established sales network, and strong relationships within the Indian healthcare sector. This agreement represents an important milestone in the Company’s expansion strategy in India, one of

Observe Medical - Company presentation with trading update

Oslo, 25 March 2026.  With reference to today's webcast, please find enclosed the presentation. Key topics: · 80% growth in quarterly sales LTM · Commercial launch of UnoMeter™ Safeti Max · Extended product offering to our distributors, capitalizing on the UnoMeter brand position · Sales in 46 countries  · Current addressable market value grown from NOK ~670m to ~2.6bn A recording of the presentation is also available at:https://qcnl.tv/p/OLaQ0Xa8KdjTtD9W3cv0PQ For further information, please contact: Jørgen Mann, CEO Observe MedicalMobile: +45 408 67 558

Innovation Norway financing at NOK 15 million disbursed and dismantling of corporate complexity to further focus on core business

Oslo, 4 March, 2026 - Observe Medical ASA (the "Company" or "Observe Medical") announces initiatives to reduce complexity and cost to invest further in growth. Innovation Norway financing The Company has received a NOK 15 million loan from Innovation Norway. The loan has been disbursed and strengthens the Company’s cash position and supports continued development of its core business activities and new product development. Dismantling complexity As communicated in the interim report announced on 27 February 2026, the Company has fully written down its investment and related book

Observe Medical ASA: Second half and full year interim report

Oslo, February 27, 2026 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the second half and the full year of 2025. Highlights · Revenue growth: UnoMeter™ portfolio revenues of NOK 7.5 million in the second half, representing an increase of 69% from the same period in 2024. For the full year the Company recorded revenues from the UnoMeter™ portfolio of NOK 18.8 million, a growth of NOK 7.3 million / +64%. · Successful recapitalisation: The Group raised NOK 58.5 million in gross proceeds, where NOK 50.5 million was settled in cash through

Observe Medical are pleased to announce our entry into the Indian market — with its more than 1,4 billion inhabitants this represents a strategic move aligned with global healthcare growth trends

Oslo, 11 February 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces entry into the Indian market with LOI signed with strong local partner and first order received. India represents one of the largest and fastest-growing healthcare markets worldwide and is projected to grow at a compound annual growth rate (CAGR) of 15–18%, with forecasts estimating the countrys healthcare market could reach USD 50 billion by 2030. Jørgen Mann, CEO of Observe Medical, commented: "We have a established a partnership with a strong local partner and taken the first order which has

Observe Medical ASA – Received Innovation Norway Loan Commitment of NOK 15 million

Oslo, 19 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSRV") has received a loan commitment from Innovation Norway for a loan of NOK 15 million to support the continued commercialisation of the Company’s UnoMeter™ product portfolio, and commercial preparation for the launch of Sippi®. The availability of the loan is subject to execution of final loan documentation and certain customary conditions precedent. Further information regarding final terms and drawdown will be provided once the loan agreement has been executed. Jørgen Mann, CEO of

Observe Medical is expanding the portfolio within the Urological drainage segment and continued market penetration

Oslo, 12 December 2025 – Observe Medical ASA (the "Company" or "Observe Medical") announces expansion of portfolio, progress on commercial journey and in the development of UnoMeter™ Safeti™ Max. The Company is launching an extension of its portfolio of products within the category of Urological Drainage. The launch includes 3 new products: a front mounted UnoMeter which is a preference in some markets and 2 Closed System products which are sterile solutions used widely within hospitals globally. In combination it is estimated the global market value of these products are at a level of 1,

Observe Medical ASA: Mandatory notification of trade by primary insider

Oslo, 22 October 2025: Observe Medical ASA (the "Company") has been informed that Jørgen Mann, CEO and primary insider in the Company, has today purchased 30,000 shares in the Company as further specified in the attached notification form. Following the purchase, Jørgen Mann holds 870,000 shares in the Company. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Observe Medical ASA: Mandatory notification of trade by close associates to primary insider

Oslo, 22 October 2025: Observe Medical ASA (the "Company") has been informed that Glimt Invest AS, a close associate to Terje Bakken, chairman of the board and primary insider of the Company, has purchased 30,000 shares in the Company as further specified in the attached notification form. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Observe Medical ASA: Registration of new share capital

Oslo, 20 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 13 October 2025 regarding the final result of the subsequent offering in the Company, where a total of 24,000,000 new shares were subscribed and allocated at a subscription price of NOK 0.50 per share. The share capital increase pertaining to the subsequent offering has today been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The Company's registered share capital is NOK 57,182,333.04 divided into 136,

Observe Medical ASA: Registration of new share capital

Oslo, 16 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 10 October 2025 regarding the extraordinary general meeting's resolution to increase the share capital of the Company by the issuance of 20,000,000 new shares to Songa Capital AS and four affiliated companies in connection with a private placement, at a subscription price of NOK 0.50 per share (the "Private Placement"). The share capital increase pertaining to the Private Placement has today been registered with the Norwegian Register of

Observe Medical ASA: Mandatory notification of trade by close associates to primary insider

Oslo, 14 October 2025: Observe Medical ASA (the "Company") has been informed that Glimt Invest AS, a close associate to Terje Bakken, chairman of the board and primary insider of the Company, has purchased 425,000 shares in the Company as further specified in the attached notification form. Following the purchase Glimt Invest AS holds 2,775,000 shares in the Company. This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Observe Medical ASA: Disclosure of major shareholdings following completion of the Private Placement and Subsequent Offering

Reference is made to the stock exchange announcements published by Observe Medical ASA (the "Company") regarding (i) the issuance of 20,000,000 new shares to complete the private placement at the extraordinary general meeting held on 10 October 2025 (the "Private Placement"), and (ii) the final result of the subsequent offering announced on 13 October 2025 (the "Subsequent Offering"). Following completion of the Private Placement, the total number of shares in the Company will be 112,148,412. Following completion and registration of both the Private Placement and the Subsequent Offering,

OBSERVE MEDICAL ASA: Preliminary results of the subsequent offering

*Correction: The preliminary count of received subscriptions indicates that 30,159,322 Offer Shares have been subscribed for. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 11 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE

OBSERVE MEDICAL ASA: Preliminary results of the subsequent offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Oslo, 10 October 2025 Reference is made to the announcement by Observe Medical ASA (the "Company" or "Observe Medical", OSE ticker "OBSVR") on 25 September 2025 regarding the launch of a subsequent offering of up to 24,000,000 new shares (the "Offer Shares")

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe